CAESAREA, Israel, May 21, 2024
/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure"
or the "Company"), developer of the ProSense® System, a
minimally-invasive cryoablation technology that destroys tumors by
freezing as an alternative to surgical tumor removal, announced
today that it will issue a press release containing its financial
and operational results as of and for the three months ended
March 31, 2024 before the Nasdaq
Stock Market opens on Tuesday, May 28,
2024. The Company will discuss such results and other
corporate developments on a conference call at 11:00 a.m. EDT that day.
Conference call & webcast info:
Tuesday, May 28, 2024, at
11:00 am EDT
US: 1-888-407-2553
Israel/International:
+972-3-9180696
A live webcast will be available at:
https://veidan.activetrail.biz/IcecureQ1-2024
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statements in this press release when it discusses the
scheduling of a conference call and the reporting of its financial
and operational results as of and for the first quarter ended
March 31, 2023. Historical results of
scientific research and clinical and preclinical trials do not
guarantee that the conclusions of future research or trials will
suggest identical or even similar conclusions. Important factors
that could cause actual results, developments and business
decisions to differ materially from those anticipated in these
forward-looking statements include, among others: the Company's
planned level of revenues and capital expenditures; the Company's
available cash and its ability to obtain additional funding; the
Company's ability to market and sell its products; legal and
regulatory developments in the United
States and other countries; the Company's ability to
maintain its relationships with suppliers, distributors and other
partners; the Company's ability to maintain or protect the validity
of its patents and other intellectual property; the Company's
ability to expose and educate medical professionals about its
products; political, economic and military instability in the
Middle East, specifically in
Israel; as well as those factors
set forth in the Risk Factors section of the Company's Annual
Report on Form 20-F for the year ended December 31, 2023 filed with the U.S. Securities
and Exchange Commission (the "SEC") on April
3, 2024, and other documents filed with or furnished to the
SEC which are available on the SEC's website, www.sec.gov. The
Company undertakes no obligation to update these statements for
revisions or changes after the date of this release, except as
required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-first-quarter-2024-financial--operational-results-on-may-28-2024-302151210.html
SOURCE IceCure Medical